Format

Send to

Choose Destination
J Med Virol. 2019 Mar 12. doi: 10.1002/jmv.25454. [Epub ahead of print]

Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection.

Author information

1
Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Beijing, China.
2
Department of Infectious Disease, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
3
Infectious Disease Department, The Third Affiliated Hospital, Sun Yet-Sen University, Guangzhou, China.
4
First Affiliated Hospital of Kunming Medical University, Kunming, China.
5
Biostatistics, Gilead Sciences, Inc, Foster City, California.
6
Virology, Gilead Sciences, Inc, Foster City, California.
7
Clinical Research, Gilead Sciences, Inc, Foster City, California.

Abstract

BACKGROUND AND AIM:

Genotype 3b hepatitis C virus (HCV) infection represents approximately 50% of patients with genotype 3 in China. We compared the efficacy of sofosbuvir (SOF) plus ribavirin (RBV) in Chinese patients with genotype 3a and 3b HCV.

METHODS:

The analyzed data are from a phase 3, open-label study of SOF plus RBV for 24 weeks conducted in China. The primary endpoint for the trial was sustained virologic response at 12 weeks after the end of therapy (SVR12).

RESULTS:

Of 126 patients included in this analysis, 58 (46%) had genotype 3a and 68 (54%) had genotype 3b. Both the subtypes were similar in age, sex, body mass index, IL28B, and baseline HCV RNA. However, more treatment-experienced and cirrhotic patients were in the genotype 3b group. All 100% of patients with genotype 3a (95% confidence interval [CI], 94-100), and 91% (95% CI, 82-97) of patients with genotype 3b achieved SVR12 (P = 0.030). For treatment-experienced patients with genotype 3b, the SVR12 rate was 73% (95% CI, 39-94) and 88% (95% CI, 64-99) among patients with and without cirrhosis (P = 1.00), respectively.

CONCLUSION:

SOF plus RBV for 24 weeks in patients with HCV genotype 3 infection resulted in high rates of SVR. However, the SVR12 rate among patients with genotype 3b was lower than that observed in patients with genotype 3a infection, particularly among treatment-experienced patients with cirrhosis.

KEYWORDS:

China; genotype 3; hepatitis C virus (HCV); ribavirin; sofosbuvir

PMID:
30861150
DOI:
10.1002/jmv.25454

Supplemental Content

Loading ...
Support Center